Gain Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Gain Therapeutics

04/08/2025 14:53

Gain Therapeutics Inc GANX.OQ GANX.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Gain Therapeutics Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Gain Therapeutics Inc is $8.00, about 82% above its last closing price of $1.44

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.18
-0.18
-0.16
Beat
11.1
Dec. 31 2025
-0.17
-0.18
-0.11
Beat
40
Sep. 30 2024
-0.22
-0.21
-0.17
Beat
20.9​
Jun. 30 2024
-0.19
-0.20
-0.42
Missed
-110
​​Mar. 31 2024
-0.29
-0.29
-0.22
Beat
24.8
Dec. 31 2023
-0.30
-0.32
-0.36
Missed
-11.6​
Sep. 30 2023
-0.45
-0.45
-0.37
Beat
17
Jun. 30 2023
-0.32
-0.31
-0.62
Missed
-101.6

This summary was machine generated August 4 at 13:53 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)